METHOD OF TREATING PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE Russian patent published in 2013 - IPC A61N5/67 A61K31/138 A61K31/4439 A61K31/734 A61K33/10 A61P1/04 G01N33/48 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating the patients with gastroesophageal reflux disease. That is ensured by the simultaneous complex introduction of drug preparations, namely a proton pump inhibitor, a prokinetic, an antacid and the intravenous blood laser exposure. The proton pump inhibitor is presented by Ultop 20 mg 2 times a day. The prokinetic is presented by Ganaton 250 mg 3 times a day. The antacid is Gaviscon 10 ml 3 times a day. The intravenous blood laser exposure is performed at wave length 0.405 mcm at output power in a disposable light guide end 1-1.5 mWt at pulse frequency 80 Hz in an continuous emission mode for 15 minutes. The 5-6 daily procedures of the intravenous blood laser exposure are required for mild gastroesophageal reflux disease, the prostaglandin E₂ level equal to 1025±112 pg/ml and more, the catalase level equal to 380±21 mcat/l and more, the ceruloplasmin level equal to 3.9±0.7 mcmole/l and more, the malonic dialdehyde level 12.6±1.5 mcmole/l and less. The 9-10 daily procedures of the intravenous blood laser exposure are required for medium and severe gastroesophageal reflux disease, the prostaglandin E₂ level equal to 1025±112 pg/ml and more, the catalase level equal to 380±21 mcat/l and more, the ceruloplasmin level equal to 3.9±0.7 mcmole/l and more, the malonic dialdehyde level 12.6±1.5 mcmole/l and less.

EFFECT: method provides higher clinical effectiveness of the drug-induced therapy, earlier reduction of the symptoms, reduced length of treatment and rate of aggravations, lower drug load on the patient's body ensured by normalised lipid peroxidation, higher level of anti-inflammatory prostaglandins, normalised microcirculatory system, balanced vegetative nervous system.

2 tbl, 2 ex